These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 26774036)

  • 1. New approach towards the synthesis of selenosemicarbazones, useful compounds for Chagas' disease.
    Pizzo C; Faral-Tello P; Yaluff G; Serna E; Torres S; Vera N; Saiz C; Robello C; Mahler G
    Eur J Med Chem; 2016 Feb; 109():107-13. PubMed ID: 26774036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural design, synthesis and pharmacological evaluation of thiazoles against Trypanosoma cruzi.
    de Oliveira Filho GB; Cardoso MVO; Espíndola JWP; Oliveira E Silva DA; Ferreira RS; Coelho PL; Anjos PSD; Santos ES; Meira CS; Moreira DRM; Soares MBP; Leite ACL
    Eur J Med Chem; 2017 Dec; 141():346-361. PubMed ID: 29031078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis of New Thiosemicarbazones and Semicarbazones Containing the 1,2,3-1H-triazole-isatin Scaffold: Trypanocidal, Cytotoxicity, Electrochemical Assays, and Molecular Docking.
    Silva BNM; Sales Junior PA; Romanha AJ; Murta SMF; Lima CHS; Albuquerque MG; D'Elia E; Rodrigues JGA; Ferreira VF; Silva FC; Pinto AC; Silva BV
    Med Chem; 2019; 15(3):240-256. PubMed ID: 30332972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel 2-arylazoimidazole derivatives as inhibitors of Trypanosoma cruzi proliferation: Synthesis and evaluation of their biological activity.
    Salerno A; Celentano AM; López J; Lara V; Gaozza C; Balcazar DE; Carrillo C; Frank FM; Blanco MM
    Eur J Med Chem; 2017 Jan; 125():327-334. PubMed ID: 27688187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The chemotherapy of Chagas disease].
    Stoppani AO
    Medicina (B Aires); 1999; 59 Suppl 2():147-65. PubMed ID: 10668258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations.
    Garcia S; Ramos CO; Senra JF; Vilas-Boas F; Rodrigues MM; Campos-de-Carvalho AC; Ribeiro-Dos-Santos R; Soares MB
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1521-8. PubMed ID: 15793134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas' disease.
    Corrales M; Cardozo R; Segura MA; Urbina JA; Basombrío MA
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1556-60. PubMed ID: 15793138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of quinones derived from natural product komaroviquinone as anti-Trypanosoma cruzi agents.
    Suto Y; Nakajima-Shimada J; Yamagiwa N; Onizuka Y; Iwasaki G
    Bioorg Med Chem Lett; 2015 Aug; 25(15):2967-71. PubMed ID: 26037321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complexation of the anti-Trypanosoma cruzi drug benznidazole improves solubility and efficacy.
    Nogueira Silva JJ; Pavanelli WR; Gutierrez FR; Alves Lima FC; Ferreira da Silva AB; Santana Silva J; Wagner Franco D
    J Med Chem; 2008 Jul; 51(14):4104-14. PubMed ID: 18570370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural and synthetic naphthoquinones active against Trypanosoma cruzi: an initial step towards new drugs for Chagas disease.
    Salas CO; Faúndez M; Morello A; Maya JD; Tapia RA
    Curr Med Chem; 2011; 18(1):144-61. PubMed ID: 21110810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An in vitro iron superoxide dismutase inhibitor decreases the parasitemia levels of Trypanosoma cruzi in BALB/c mouse model during acute phase.
    Olmo F; Urbanová K; Rosales MJ; Martín-Escolano R; Sánchez-Moreno M; Marín C
    Int J Parasitol Drugs Drug Resist; 2015 Dec; 5(3):110-6. PubMed ID: 26236582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cysteine protease inhibitor cures Chagas' disease in an immunodeficient-mouse model of infection.
    Doyle PS; Zhou YM; Engel JC; McKerrow JH
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3932-9. PubMed ID: 17698625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo trypanocidal activities of 8-methoxy-3-(4-nitrobenzoyl)-6-propyl-2H-cromen-2-one, a new synthetic coumarin of low cytotoxicity against mammalian cells.
    Brancaglion GA; Toyota AE; Cardoso Machado JV; Fernandes Júnior AÁ; Silveira AT; Vilas Boas DF; Dos Santos EG; Caldas IS; Carvalho DT
    Chem Biol Drug Des; 2018 Nov; 92(5):1888-1898. PubMed ID: 29992719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of immunosuppression and benzonidazole on Trypanosoma cruzi parasitism during experimental acute Chagas' disease.
    Okumura M; Mester M; Iriya K; Amato Neto V; Gama-Rodrigues J
    Transplant Proc; 1994 Jun; 26(3):1587-9. PubMed ID: 8030049
    [No Abstract]   [Full Text] [Related]  

  • 15. Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
    Martín-Escolano R; Marín C; Vega M; Martin-Montes Á; Medina-Carmona E; López C; Rotger C; Costa A; Sánchez-Moreno M
    Bioorg Med Chem; 2019 Mar; 27(5):865-879. PubMed ID: 30728107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the in vivo therapeutic properties of (-)-cubebin and (-)-hinokinin against Trypanosoma cruzi.
    Esperandim VR; da Silva Ferreira D; Rezende KC; Cunha WR; Saraiva J; Bastos JK; e Silva ML; de Albuquerque S
    Exp Parasitol; 2013 Apr; 133(4):442-6. PubMed ID: 23274812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of thiosemicarbazones and semicarbazones as potential agents anti-Trypanosoma cruzi.
    Soares RO; Echevarria A; Bellieny MS; Pinho RT; de Leo RM; Seguins WS; Machado GM; Canto-Cavalheiro MM; Leon LL
    Exp Parasitol; 2011 Dec; 129(4):381-7. PubMed ID: 21939658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a new amide-containing thiazole as a drug candidate for treatment of Chagas' disease.
    Álvarez G; Varela J; Cruces E; Fernández M; Gabay M; Leal SM; Escobar P; Sanabria L; Serna E; Torres S; Figueredo Thiel SJ; Yaluff G; Vera de Bilbao NI; Cerecetto H; González M
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1398-404. PubMed ID: 25512408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trypanocidal activity of the phenyl-substituted analogue of furamidine DB569 against Trypanosoma cruzi infection in vivo.
    de Souza EM; Oliveira GM; Boykin DW; Kumar A; Hu Q; De Nazaré C Soeiro M
    J Antimicrob Chemother; 2006 Sep; 58(3):610-4. PubMed ID: 16854954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, structure-activity relationship and in vivo efficacy of piperazine analogues of fenarimol as inhibitors of Trypanosoma cruzi.
    Keenan M; Alexander PW; Diao H; Best WM; Khong A; Kerfoot M; Thompson RC; White KL; Shackleford DM; Ryan E; Gregg AD; Charman SA; von Geldern TW; Scandale I; Chatelain E
    Bioorg Med Chem; 2013 Apr; 21(7):1756-63. PubMed ID: 23462713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.